Alicia Morgans, Associate Professor of Medicine at Northwestern University, shares her thoughts on genetically informed treatment for advanced and metastatic prostate cancer. Germline and somatic testing can have implications for patients in terms of their therapeutics and the main mutations. Morgans discusses the important germline and somatic mutations as well as the current data from…
Program: Beyond Androgen Blockade – New Pathways and Novel Treatments in mHSPC and mCRPC Part of an Independent Medical Education Initiative Supported by LOXO@Lilly Biographies:…
Hiten Patel discusses his team’s study on the use of neoadjuvant chemotherapy before radical cystectomy for muscle-invasive bladder cancer. The research, motivated by low utilization…
prostate cancer, Brief Androgen Suppression and Stereotactic Radiation Therapy, High-Risk Prostate Cancer, FASTR trial, FASTR-2 Trials, stereotactic ablative radiotherapy (SABR), SABR in high-risk prostate cancer.
Massimo (Max) Loda discusses his team’s research on the role of the microenvironment in prostate cancer progression, published in Nature Communications. The study focuses on…
prostate cancer, Advanced Prostate Cance, major adverse cardiac events (MACE), HERO study, concomitant Cardiovascular Therapies, Relugolix, Leuprolide, Relugolix versus Leuprolide, concomitant cardiovascular medications (CV), androgen…
InPACT trial, penile cancer, Squamous Cell Cancer of the Penis, Radiotherapy in the Management of Squamous Cell Cancer of the Penis, InPact trial, ECOG-ACRIN, GOG…
Program: State-of-the-Art Interdisciplinary Management of Prostate Cancer This series is part of an Independent Medical Education Initiative Supported by BAYER U.S. LLC PHARMACEUTICALS Biographies: Tian…
Daniel Castellano emphasizes the importance of multidisciplinary approaches in patient care and research. He advocates for precision medicine in genitourinary tumors, highlighting advancements in prostate…
bladder cancer, muscle-invasive bladder cancers (MIBC), PURE-01 trial, ABACUS trial, NABUCCO trial, tumor mutational burden (TMB), PI3K-AKT-mTOR signaling, tyrosine kinase receptors/RAS. Alterations, FGFR3 mutations, DNA…
Sam Washington and Isla Garraway discuss the Prostate Cancer Foundation’s new screening guidelines for prostate cancer in Black men. Dr. Garraway highlights the guidelines’ development…
